Biopharmx Corp (BPMX) Short Interest Up 3.0% in October

Biopharmx Corp (NYSE:BPMX) was the target of a significant growth in short interest in October. As of October 13th, there was short interest totalling 4,271,767 shares, a growth of 3.0% from the September 29th total of 4,147,107 shares. Based on an average daily volume of 866,539 shares, the short-interest ratio is presently 4.9 days. Approximately 7.4% of the shares of the company are sold short.

Shares of Biopharmx Corp (NYSE BPMX) opened at 0.2051 on Friday. The stock’s 50 day moving average price is $0.28 and its 200-day moving average price is $0.43. The firm’s market cap is $16.34 million. Biopharmx Corp has a 52-week low of $0.18 and a 52-week high of $0.90.

TRADEMARK VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2017/10/29/biopharmx-corp-bpmx-short-interest-up-3-0-in-october.html.

Biopharmx Corp Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply